Navigation Links
Texas A&M biologists prove ZOLOFT packs potential to fight fungal meningitis
Date:7/25/2012

New research conducted by biologists at Texas A&M University suggests that ZOLOFT, one of the most widely prescribed antidepressants in the world, also packs a potential preventative bonus potent mechanisms capable of inhibiting deadly fungal infections.

The findings are the result of a two-year investigation by Xiaorong Lin, assistant professor of biology, and Matthew S. Sachs, professor of biology, involving sertraline hydrocholoride (ZOLOFT) and its effects on Cryptococcus neoformans, the major causative agent of fungal meningitis specifically, cryptococcal meningitis, which claims more than half a million lives worldwide each year, according to a 2009 Center for Disease Control (CDC) report.

Their research, funded with grants from the American Heart Association (AHA), the Norman Hackerman Advanced Research Program, and the National Institutes of Health (NIH), is published in the June issue of the American Society of Microbiology journal Antimicrobial Agents and Chemotherapy. Their research team includes Ph.D. candidate Bing Zhai and postdoctoral fellows Cheng Wu and Linqi Wang.

"The point here is that if there is a drug that already exists, is known to be well-tolerated, and has alternative uses, that's a good thing," Sachs says. "The billion dollars it would take to bring a drug to the market that's already done."

C. neoformans is a potentially dangerous fungal pathogen found in many soils throughout the world that may cause systemic infections, particularly involving the central nervous system. In most cases, the microscopic, airborne fungal cells of C. neoformans cause asymptomatic colonization in the lungs. However, Lin says the fungus is particularly aggressive in people with weakened immune systems and can spread to other parts of the body, such as the brain and spinal cord, resulting in cryptococcal meningitis a condition that, in absence of treatment, is fatal.

Lin participated in a previous study to screen a collection of FDA-approved drugs in a John Hopkins Clinical Compound Library to determine if any contained fungicidal agents. Although sertraline was shown to only moderately inhibit the effects of common fungal strains like Aspergillus nidulans, a genus of common mold often found on spoiled food, and Candida, a genus of yeast often associated with mammals, sertraline was found to be particularly effective against C. neoformans.

A follow-up investigation of sertraline in a mouse model of systemic cryptococcosis revealed that it combats infection similar to fluconazole, an antifungal drug used commonly since the early 1990s. Moreover, a drug combination of sertraline and fluconazole was found to work more efficiently than either drug alone.

Lin says that even though the infection ultimately proved fatal in the mice study, sertraline as a cryptoccol treatment still holds promise. Because sertraline reduced the overall fungal burden within the mice and also possesses the desirable ability to cross the blood-brain barrier as an antidepressant, there is still hope it can be altered to serve as a viable treatment option.

"The problem for many current antifungal drugs is that many cannot go to the brain, and it's very difficult for a lot of compounds to reach the brain in the first place," Lin says. "So, you run into the problem of not killing all the fungus or having a very low level of fungus still exist. The fact is, this antidepressant can cross the blood-brain barrier and can get into the tissue at high concentrations."

It remains unclear exactly what dosage and concentration of sertraline is necessary to completely eliminate cryptococcosis, especially cryptococcal meningitis, but Lin and Sachs hope those answers will come to light with further testing.

"If this becomes useful, it could represent a truly significant increase in our ability to help people with brain cryptococcal infections," Sachs adds.


'/>"/>
Contact: Shana Hutchins
shutchins@science.tamu.edu
979-862-1237
Texas A&M University
Source:Eurekalert

Related medicine news :

1. University of Texas Medical Branch to study hospital readmission
2. Ordinary chickens may be extraordinary in fighting cancer, says Texas A&M researcher
3. Texas Back Institute Becomes Official Spine Specialist for FC Dallas and the Frisco RoughRiders
4. Inhaled Steroids Lead to Big Drop in Asthma Deaths at Texas Hospital: Study
5. New research seeks to improve survival for myeloma and lymphoma patients
6. New angioplasty procedure improves blood flow in blocked arteries to extremities
7. Strobe eyewear training improves visual memory
8. Meta-analysis: Interventions improve depression in cancer patients
9. HPV improves survival for African-Americans with throat cancer
10. Herbal remedy used to treat hepatitis C proves ineffective, Penn study finds
11. New targeting technology improves outcomes for patients with atrial fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... Ariz. (PRWEB) , ... June 20, 2017 , ... ... Natural Brands®, makers of SweetLeaf® Stevia Sweetener, Michael P. May, Ph.D., recently accepted ... Sun Corridor Export Recognition Program selected Wisdom Natural Brands (WNB), and 16 other ...
(Date:6/20/2017)... (PRWEB) , ... June 20, 2017 , ... ... the security systems industry has been selected as the partner of choice by ... a passenger railroad service that provides medium- and long-distance intercity service in the ...
(Date:6/20/2017)... ... June 20, 2017 , ... John D'Eri, CEO of ... Leader in Adult Autism Award during the Autism Society of America 's ... The Daniel Jordan Fiddle Foundation (DJFF) was founded in 2002 as the ...
(Date:6/20/2017)... , ... June 20, 2017 , ... ... patient’s bedside, would like to officially welcome Anthony Stanowski, DHA, FACHE to the ... Stanowski whose insight and expertise in healthcare will provide invaluable direction for the ...
(Date:6/20/2017)... ... ... The law firm of Momkus McCluskey Roberts LLC congratulates attorney Gerald ... Association’s Board of Directors. Cassioppi officially took on the leadership role during the DCBA’s ... McCluskey Roberts LLC attorney Stacey A. McCullough was also installed as the DCBA’s second ...
Breaking Medicine News(10 mins):
(Date:5/30/2017)... 2017 Therapix Biosciences Ltd. (Nasdaq: TRPX), ... the development of cannabinoid-based drugs, today announced that ... at three upcoming scientific and investor conferences in ... Invitational: ...                     Wednesday, June ...
(Date:5/26/2017)... Calif. , May 25, 2017  In response ... States , Direct Relief is working with Pfizer ... Naloxone available at no cost to community health centers, ... nonprofit providers nationwide. "Pfizer has a ... to medicines and ensuring patient safety through educational activities," ...
(Date:5/22/2017)... May 22, 2017  Lilac Corp, the company ... the launch of a new website . ... of a clinical study that showed surprising clearance ... Gene-Eden-VIR/Novirin in individuals suffering from HPV warts, precancerous, ... there are no other treatments that clear the ...
Breaking Medicine Technology: